Combination of attenuated measles vaccine (Schwarz) with meningococcus A and A + C vaccine. 1978

N Ajjan, and M T Fayet, and G Biron, and C Charbonnier, and A Nicolas, and R Triau, and M Roumiantzeff

There is an obvious interest in a combined meningococcus-measles vaccine since the two diseases are widespread and serious in Third World countries among children under five years of age. The purpose of our study was to show the safety and effectiveness of such a combined preparation. The study covered 110 children between 8 months and 4 years of age who were followed systematically in a maternal child health center in the Paris area. Only 93 of them were checked before and after the immunization. The serologic titrations by the hemagglutination assay (IHA) for measles, and by radioimmunological assay (RIA) for meningococcus A and C showed that the Schwarz strain measles vaccine combined with meningococcus A or the association A+C does not interfere with the increase of A or C titers. 100% of the children showed a seroconversion equal to or less than 2 micrograms per ml, in the case of meningococcus A, as well as for C, regardless of age. Furthermore, 88% of the subjects showed a titer greater than or equal to 4 micrograms for the meningococcus A and 79% for C. On the other hand, meningococcus A or the association A+C seem to depress measles vaccine activity. Nevertheless, more than 80% of the children tested showed seroconversion when the measles vaccine was combined with meningococcus A, and only 69% when combined with meningococcus A and C.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008457 Measles A highly contagious infectious disease caused by MORBILLIVIRUS, common among children but also seen in the nonimmune of any age, in which the virus enters the respiratory tract via droplet nuclei and multiplies in the epithelial cells, spreading throughout the MONONUCLEAR PHAGOCYTE SYSTEM. Rubeola
D008458 Measles Vaccine A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed) Vaccine, Measles
D008585 Meningitis, Meningococcal A fulminant infection of the meninges and subarachnoid fluid by the bacterium NEISSERIA MENINGITIDIS, producing diffuse inflammation and peri-meningeal venous thromboses. Clinical manifestations include FEVER, nuchal rigidity, SEIZURES, severe HEADACHE, petechial rash, stupor, focal neurologic deficits, HYDROCEPHALUS, and COMA. The organism is usually transmitted via nasopharyngeal secretions and is a leading cause of meningitis in children and young adults. Organisms from Neisseria meningitidis serogroups A, B, C, Y, and W-135 have been reported to cause meningitis. (From Adams et al., Principles of Neurology, 6th ed, pp689-701; Curr Opin Pediatr 1998 Feb;10(1):13-8) Meningitis, Neisseria,Neisseria Meningitis,Meningitis, Meningococcal, Serogroup A,Meningitis, Meningococcal, Serogroup B,Meningitis, Meningococcal, Serogroup C,Meningitis, Meningococcal, Serogroup W-135,Meningitis, Meningococcal, Serogroup W135,Meningitis, Meningococcal, Serogroup Y,Meningitis, Meningococcic,Meningococcal Meningitis, Serogroup A,Meningococcal Meningitis, Serogroup B,Meningococcal Meningitis, Serogroup C,Meningococcal Meningitis, Serogroup W-135,Meningococcal Meningitis, Serogroup W135,Meningococcal Meningitis, Serogroup Y,Serogroup A Meningococcal Meningitis,Serogroup B Meningococcal Meningitis,Serogroup C Meningococcal Meningitis,Serogroup W-135, Meningococcal Meningitis,Serogroup W135, Meningococcal Meningitis,Serogroup Y, Meningococcal Meningitis,Meningococcal Meningitis,Meningococcal Meningitis, Serogroup W 135,Neisseria Meningitides,Serogroup W 135, Meningococcal Meningitis
D009345 Neisseria meningitidis A species of gram-negative, aerobic BACTERIA. It is a commensal and pathogen only of humans, and can be carried asymptomatically in the NASOPHARYNX. When found in cerebrospinal fluid it is the causative agent of cerebrospinal meningitis (MENINGITIS, MENINGOCOCCAL). It is also found in venereal discharges and blood. There are at least 13 serogroups based on antigenic differences in the capsular polysaccharides; the ones causing most meningitis infections being A, B, C, Y, and W-135. Each serogroup can be further classified by serotype, serosubtype, and immunotype. Diplokokkus intracellularis meningitidis,Meningococcus,Micrococcus intracellularis,Micrococcus meningitidis,Micrococcus meningitidis cerebrospinalis,Neisseria weichselbaumii
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D000907 Antibodies, Bacterial Immunoglobulins produced in a response to BACTERIAL ANTIGENS. Bacterial Antibodies

Related Publications

N Ajjan, and M T Fayet, and G Biron, and C Charbonnier, and A Nicolas, and R Triau, and M Roumiantzeff
January 1965, Archiv fur die gesamte Virusforschung,
N Ajjan, and M T Fayet, and G Biron, and C Charbonnier, and A Nicolas, and R Triau, and M Roumiantzeff
March 1969, Nihon Ishikai zasshi. Journal of the Japan Medical Association,
N Ajjan, and M T Fayet, and G Biron, and C Charbonnier, and A Nicolas, and R Triau, and M Roumiantzeff
January 1965, Nihon Ika Daigaku zasshi,
N Ajjan, and M T Fayet, and G Biron, and C Charbonnier, and A Nicolas, and R Triau, and M Roumiantzeff
January 1973, Annali Sclavo; rivista di microbiologia e di immunologia,
N Ajjan, and M T Fayet, and G Biron, and C Charbonnier, and A Nicolas, and R Triau, and M Roumiantzeff
March 1967, Nihon Shonika Gakkai zasshi. Acta paediatrica Japonica,
N Ajjan, and M T Fayet, and G Biron, and C Charbonnier, and A Nicolas, and R Triau, and M Roumiantzeff
January 1967, Progress in immunobiological standardization,
N Ajjan, and M T Fayet, and G Biron, and C Charbonnier, and A Nicolas, and R Triau, and M Roumiantzeff
June 1970, Electroencephalography and clinical neurophysiology,
N Ajjan, and M T Fayet, and G Biron, and C Charbonnier, and A Nicolas, and R Triau, and M Roumiantzeff
August 1961, American journal of pharmacy and the sciences supporting public health,
N Ajjan, and M T Fayet, and G Biron, and C Charbonnier, and A Nicolas, and R Triau, and M Roumiantzeff
February 1980, EPI newsletter,
N Ajjan, and M T Fayet, and G Biron, and C Charbonnier, and A Nicolas, and R Triau, and M Roumiantzeff
January 1965, Archiv fur die gesamte Virusforschung,
Copied contents to your clipboard!